Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Answer: Can you identify this condition?

Christian Petropolis, Vimal Prajapati and Benjamin Barankin
Canadian Family Physician November 2010, 56 (11) 1151-1152;
Christian Petropolis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vimal Prajapati
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Barankin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Answer to Dermacase continued from page 1149

5. Superficial basal cell carcinoma

Basal cell carcinoma (BCC) is a cutaneous malignancy derived from nonkeratinizing cells that originate in the basal layer of the epidermis. It is the most common type of skin cancer in humans. The 4 main subtypes include nodular, superficial, pigmented, and morpheaform or sclerosing. The primary risk factors for developing BCC include fair skin colour and increased sun exposure.1 The incidence of BCC is 19 times higher in the white population compared with darker-skinned populations. Additional risk factors include immunosuppression and genetic skin disorders such as xeroderma pigmentosum.2

Figure

Superficial BCC is the second most common subtype, accounting for 9.0% to 17.5% of all BCCs.1 The typical presentation is a solitary, well-defined, erythematous plaque with variable overlying scales and a threadlike, slightly raised, pearly border.3 Size can range from a few millimetres to several centimetres in diameter. By far most cases are asymptomatic. Rarely, variable pigmentation or ulceration might be present. Unlike other BCC subtypes, which are most commonly found on the head and neck, superficial BCC predominantly occurs on the trunk and extremities.1 This has led to speculation that superficial BCC development is linked with intense intermittent rather than cumulative sun exposure, although this association has yet to be confirmed.1,4–6 Superficial BCC also differs from other BCC subtypes in that it tends to have an earlier age of onset and more frequently affects women.1,7

Diagnosis

Superficial BCC is most often diagnosed clinically. The differential diagnosis includes a solitary plaque of nummular eczema or psoriasis, actinic keratosis, Bowen disease (ie, squamous cell carcinoma in situ), superficial spreading melanoma, and extramammary Paget disease.3 Patients with nummular eczema or psoriasis usually have multiple sites of involvement and most will describe a previous history of similar lesions. Nummular eczema preferentially occurs on the distal extremities and plaques tend to be very pruritic. Psoriasis classically occurs on the extensor surfaces of the body, especially the elbows, knees, and buttocks, and plaques tend to be thicker with an overlying scale that is silver in colour. Patients with psoriasis might also have associated scalp, nail, or joint findings. Although most cases of nummular eczema and psoriasis are readily distinguishable from superficial BCC, any solitary plaque of “eczema” or “psoriasis” unresponsive to treatment should be considered suspicious for superficial BCC; skin biopsy should be performed in these cases.

Actinic keratoses tend to be smaller in size and less well defined, and any adherent scale is often felt before it can be seen. In addition, they occur almost exclusively on the head, neck, and dorsa of the hands and forearms, and rarely on the trunk.

Bowen disease is clinically indistinguishable from superficial BCC. Likewise, superficial BCC with variable pigmentation cannot be differentiated with certainty from superficial spreading melanoma. As such, skin biopsy should be performed for all scaly, erythematous plaques with pigmentation.

Extramammary Paget disease is also very similar in clinical appearance to superficial BCC. However, this cutaneous malignancy is rare and typically symptomatic, with frequent reports of burning and intense pruritus. Although extramammary Paget disease most often occurs on apocrine gland–bearing skin (ie, groin, axillae, vulva, perianal region, scrotum, and penis), it is included in the differential diagnosis of superficial BCC because ectopic cases occurring on areas of the body relatively free of apocrine glands (ie, chest and abdomen) have also been reported.8

Treatment

As with other BCC subtypes, superficial BCC rarely metastasizes, and morbidity is due to local tissue invasion and destruction.3 The goal of treatment is to eradicate the tumour while providing an acceptable cosmetic outcome for the patient. Treatment for superficial BCC includes both surgical and nonsurgical options.

For primary superficial BCC occurring at a low-risk anatomic site (eg, trunk and extremities) with distinct clinical borders and size less than 2 cm in diameter, several effective treatment options are available: standard surgical excision, electrodesiccation and curettage, liquid nitrogen cryotherapy, imiquimod 5% cream, 5-fluorouracil 5% cream, and photodynamic therapy.3,9 Of these treatments, it is important to note that only standard surgical excision allows for verification of histologic clearance.3

Standard surgical excision is highly effective, with recurrence rates of less than 2% reported at 5 years when lesions are excised with histologically clear margins.8 Excision using 4- to 5-mm margins will completely remove the tumour in approximately 95% of cases.9 Electrodesiccation and curettage and liquid nitrogen cryotherapy have reported cure rates of 92.3% and 99%, respectively, for appropriately selected low-risk BCC when performed by experienced practitioners.10,11 With regard to cryotherapy, double freeze-thaw treatment cycles are generally recommended for facial lesions, whereas a single treatment cycle is sufficient for truncal lesions.9 Double freeze-thaw treatment cycles involve 2 treatments of liquid nitrogen, with the second treatment implemented only after the frozen site has had sufficient time to spontaneously thaw without assistance following the first treatment.9,10 Adverse effects of cryotherapy include pain and discomfort during treatment as well as dyspigmentation, redness, and blistering after treatment, which can take 2 to 3 weeks to heal.10

Topical immunotherapy with imiquimod 5% cream applied 5 times weekly for 6 weeks is a safe and effective treatment option as well. A complete histologic clearance rate of 82% was reported with this dosing regimen in a phase 3, randomized, vehicle-controlled study.12 Almost all patients will experience moderate to severe local skin reactions at the application site, which can include erythema, edema, erosion or ulceration, and scabbing or crusting. Patients should be warned about these adverse effects before treatment. If the local skin reactions are severe, treatment can be temporarily discontinued and resumed once symptoms have subsided. Long-term data on recurrence rates are limited at this time.12 Topical immunotherapy with 5-fluorouracil 5% cream applied twice daily for 12 weeks can also be used in the treatment of superficial BCC, with histologic cure rates of 90%.13 Erythema and mild scarring are the main adverse effects. Photodynamic therapy is another effective treatment option, with cure rates ranging from 86% to 92% and superior cosmetic outcomes when compared with standard surgical excision and cryotherapy.14,15

For primary superficial BCC located at a high-risk anatomic site (eg, central face, around the eyes, nose, lips, and ears), with indistinct clinical borders or size greater than 2 cm in diameter, or for any recurrent superficial BCCs, Mohs micrographic surgery is the preferred treatment. Referral to a dermatologist specializing in Mohs micrographic surgery is required. Extremely high overall 5-year cure rates of 99% and 94% for primary and recurrent high-risk BCCs, respectively, have been reported in the literature. For patients unwilling or unable to tolerate surgery, radiation therapy can also be offered.9

Conclusion

With appropriate treatment, the prognosis of superficial BCC is excellent. However, regardless of subtype, routine follow-up is recommended for all patients with primary BCC in order to monitor for local recurrence or the development of new primary BCCs at other sites. In addition, patients with a history of BCC are at an increased risk of developing melanoma. Therefore, periodic skin self-examination and sun safety measures (eg, sun-protective clothing, sunscreen with a sun-protective factor of at least 30, and avoidance of midday sun) should be recommended to all patients.3

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Scrivener Y,
    2. Grosshans E,
    3. Cribier B
    . Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002;147(1):41-7.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Roewert-Huber J,
    2. Lange-Asschenfeldt B,
    3. Stockfleth E,
    4. Kerl H
    . Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol 2007;157(Suppl 2):47-51.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Wolff K,
    2. Goldsmith LA,
    3. Katz SI,
    4. Gilchrest BA,
    5. Paller AS,
    6. Leffell DJ
    . Fitzpatrick’s dermatology in general medicine. 7th ed. New York, NY: McGraw-Hill; 2008.
  4. ↵
    1. Raasch BA,
    2. Buettner PG,
    3. Garbe C
    . Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol 2006;155(2):401-7.
    OpenUrlCrossRefPubMed
    1. McCormack CJ,
    2. Kelly JW,
    3. Dorevitch AP
    . Differences in age and body site distribution of histological subtypes of basal cell carcinoma. A possible indicator of different causes. Arch Dermatol 1997;133(5):593-6.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Pelucchi C,
    2. Di Landro A,
    3. Naldi L,
    4. La Vecchia C,
    5. Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology
    . Risk factors for histological types and anatomic sites of cutaneous basal-cell carcinoma: an Italian case–control study. J Invest Dermatol 2007;127(4):935-44. Epub 2006 Oct 19.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Betti R,
    2. Radaelli G,
    3. Mussino F,
    4. Menni S,
    5. Crosti C
    . Anatomic location and histopathologic subtype of basal cell carcinomas in adults younger than 40 or 90 and older: any difference? Dermatol Surg 2009;35(2):201-6.
    OpenUrlPubMed
  7. ↵
    1. Griffiths RW,
    2. Suvarna SK,
    3. Stone J
    . Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg 2005;58(6):795-805.
    OpenUrlPubMed
  8. ↵
    1. Telfer NR,
    2. Colver GB,
    3. Morton CA,
    4. British Association of Dermatologists
    . Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008;159(1):35-48.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Kuflik EG
    . Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg 2004;30(2 Pt 2):297-300.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Rowe DE,
    2. Carroll RJ,
    3. Day CL Jr.
    . Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989;15(3):315-28.
    OpenUrlPubMed
  11. ↵
    1. Geisse J,
    2. Caro I,
    3. Lindholm J,
    4. Golitz L,
    5. Stampone P,
    6. Owens M
    . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50(5):722-33.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Gross K,
    2. Kircik L,
    3. Kricorian G
    . 5% 5-fluorouracil cream in the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 2007;33(4):433-9. discussion 440.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Basset-Seguin N,
    2. Ibbotson SH,
    3. Emtestam L,
    4. Tarstedt M,
    5. Morton C,
    6. Maroti M,
    7. et al
    . Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008;18(5):547-53. Epub 2008 Aug 8.
    OpenUrlPubMed
  14. ↵
    1. Szeimies RM,
    2. Ibbotson S,
    3. Murrell DF,
    4. Rubel D,
    5. Frambach Y,
    6. de Berker D,
    7. et al
    . A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008;22(11):1302-11. Epub 2008 Jul 2.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 56 (11)
Canadian Family Physician
Vol. 56, Issue 11
1 Nov 2010
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Answer: Can you identify this condition?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Answer: Can you identify this condition?
Christian Petropolis, Vimal Prajapati, Benjamin Barankin
Canadian Family Physician Nov 2010, 56 (11) 1151-1152;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Answer: Can you identify this condition?
Christian Petropolis, Vimal Prajapati, Benjamin Barankin
Canadian Family Physician Nov 2010, 56 (11) 1151-1152;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • 5. Superficial basal cell carcinoma
    • Diagnosis
    • Treatment
    • Conclusion
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Question: Can you identify this condition?
  • Question: Can you identify this condition?
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Is 45 the new 50 in colorectal cancer screening?
  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
Show more Practice

Dermacase

  • Question: Can you identify this condition?
  • Answer: Can you identify this condition?
  • Question: Can you identify this condition?
Show more Dermacase

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2022 by The College of Family Physicians of Canada

Powered by HighWire